The granulomatous disease-vitamin D paradox is clinically important — in sarcoidosis, tuberculosis, and some lymphomas, activated macrophages within granulomata express 1-alpha-hydroxylase enzyme autonomously (independent of renal regulation by PTH and calcium), converting 25-OH-D to the active 1,25-OH-D. This autonomous production causes hypercalcaemia and hypercalciuria even when serum 25-OH-D is low or normal. In these conditions, vitamin D supplementation can worsen hypercalcaemia, so replacement decisions need specialist input — increasing the substrate (25-OH-D) available for autonomous conversion by macrophages will worsen the hypercalcaemia. The practical implication: before prescribing vitamin D replacement for low 25-OH-D, check adjusted calcium. If calcium is elevated in the context of low 25-OH-D: check PTH, consider 1,25-OH₂-D, arrange chest imaging and seek specialist advice (respiratory/rheumatology/endocrinology) before supplementation; also consider primary hyperparathyroidism, malignancy, excess intake, renal disease and medication causes. ACE is not sensitive or specific enough to be a routine diagnostic test. The normal rule is: low 25-OH-D + high PTH + low-normal calcium = simple deficiency requiring supplementation. Low 25-OH-D + suppressed PTH + high calcium = PTH-independent hypercalcaemia (malignancy, granulomatous disease, excess intake) until proved otherwise.

The UK vitamin D paradox: despite being an island with a relatively mild climate, the UK has extremely high rates of vitamin D deficiency — because at UK latitude, UV-B radiation from about October to early March is insufficient to stimulate cutaneous vitamin D synthesis even on a sunny day. The sun's angle is too low for the UV-B wavelengths (280-315 nm) to penetrate the atmosphere sufficiently. This means that vitamin D synthesised during the summer months must be stored in adipose tissue and liver to last through the winter. People with dark skin, who have higher melanin concentrations reducing UV-B penetration, cannot synthesise adequate vitamin D even in UK summer sunlight — needing longer sun exposure than pale-skinned individuals to produce the same amount of vitamin D. This explains why South Asian, Black African, and Black Caribbean populations in the UK have dramatically higher rates of vitamin D deficiency than white populations living in the same geographic area. SACN (Scientific Advisory Committee on Nutrition) 2016 report established the current UK recommendation: a reference nutrient intake of 10 micrograms (400 IU) a day throughout the year for everyone aged 4 years and over, with a safe intake of 10 micrograms a day for ages 1–4 and 8.5–10 micrograms a day for infants. DHSC advice: everyone over 1 year should consider 10 micrograms daily in autumn and winter, and all year for those at higher risk.

The bisphosphonate-vitamin D deficiency interaction is a critical prescribing safety point — oral bisphosphonates (alendronic acid, risedronate) bind to and inhibit osteoclast activity, reducing bone resorption. In a vitamin D-deficient patient, calcium absorption from the gut is already reduced (due to low 1,25-OH-D). When bisphosphonate further reduces bone resorption (the secondary source of calcium for maintaining serum calcium), severe hypocalcaemia can result. Cases of severe hypocalcaemia, tetany, and seizures have been reported after bisphosphonate initiation in vitamin D-deficient patients. The safe practice: denosumab — ensure adequate calcium and vitamin D and correct hypocalcaemia before administration; monitoring is particularly important in advanced CKD (eGFR <30) (local denosumab shared-care protocol). IV zoledronate — check renal function, calcium and vitamin D status before infusion. Oral bisphosphonates — vitamin D correction is important, but a loading regimen is not automatically required if deficiency is mild and treatment is clinically urgent; follow the osteoporosis pathway.

Antiepileptic drug-vitamin D interaction is one of the most clinically significant and underappreciated drug-nutrient interactions — enzyme-inducing antiepileptics (carbamazepine, phenytoin, phenobarbitone, primidone) are potent inducers of CYP3A4 and CYP2C9 hepatic enzymes, which accelerate the catabolism of 25-OH-D to inactive metabolites, causing vitamin D deficiency and secondary hyperparathyroidism even in patients with adequate sunlight exposure and dietary vitamin D. The clinical consequences: reduced bone mineral density, increased fracture risk, and osteomalacia in severe deficiency. In people taking long-term enzyme-inducing antiepileptic medicines, review vitamin D supplementation and bone-health risk: consider 400–1,000 IU daily or the local neurology/osteoporosis protocol, assess fracture risk, and arrange DXA according to age, duration of treatment, fracture risk and other clinical factors rather than automatically every 2–3 years. Any change of antiepileptic requires neurology input.

The practical vitamin D prescribing distinction between cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) matters — D3 (cholecalciferol) is the natural form synthesised in human skin and is more potent at raising serum 25-OH-D than the equivalent dose of D2 (ergocalciferol), which is the plant-derived form. UK NHS prescribing predominantly uses D3 (Invita D3, Fultium D3, Aviticol) for treatment and D3-containing supplements (Adcal-D3, Calcichew D3) for combined calcium and vitamin D supplementation in osteoporosis. The weekly high-dose preparations (Invita D3 25,000 IU weekly or 50,000 IU monthly) are particularly useful for loading regimens and for patients with malabsorption who cannot achieve adequate levels with daily supplements. GPs should prescribe by dose in IU or mcg (not by brand) to allow pharmacist substitution with equivalent products.

The loading dose rationale: vitamin D is fat-soluble and has a half-life of approximately 4-6 weeks in blood, but the body stores are in adipose tissue and liver, with a much longer effective duration. A loading regimen rapidly repletes tissue stores and achieves therapeutic serum levels within 2-4 weeks, whereas daily low-dose supplementation alone in a severely deficient patient would take 3-6 months to normalise. The total cumulative loading dose (300,000 IU, approximately 7.5 mg) should be clearly documented with its duration and the planned maintenance dose — toxicity risk depends on cumulative dosing, product errors, renal function, calcium intake and individual susceptibility, so avoid prolonged high-dose prescribing without review (SPS). The practical prescribing choices for loading: (1) weekly 50,000 IU sachets (Invita D3 — dissolve in water) for 6 weeks = 300,000 IU total — good compliance; (2) daily 4,000 IU for 10 weeks = 280,000 IU total (ROS regimen) — suits patients who prefer daily routine; (3) intramuscular preparations only under a specialist malabsorption or bariatric protocol.

Healthy Start vitamins are a significant health equity intervention that GPs should actively promote — they are available free to: pregnant women who receive qualifying benefits, mothers with children under 4 who receive qualifying benefits, and pregnant women under 18 (regardless of benefits status). The vitamins contain 400 mcg folic acid + 70 mg vitamin C + 10 micrograms (400 IU) vitamin D — addressing three key nutritional deficiencies in at-risk populations simultaneously. Despite being free, uptake is poor, often because the vitamins are not mentioned at antenatal appointments. GPs and midwives should mention Healthy Start vitamins at every first antenatal appointment with eligible women. The Healthy Start scheme also provides vouchers for fresh fruit, vegetables, pulses, and plain cow's milk for eligible families — GPs can signpost to Healthy Start (www.healthystart.nhs.uk) for application.

The vitamin D and falls prevention evidence is weaker than often assumed — a Cochrane review (Gillespie et al. 2012) found vitamin D did not reduce falls in community-dwelling older people overall, though it may in those with low vitamin D levels. The mechanism: vitamin D has direct effects on muscle function (VDR in skeletal muscle regulate contractile protein synthesis), which may improve muscle strength in deficiency, but this has not translated into a consistent reduction in falls. NICE NG249 (Falls, 2025, rec 1.3.4) finds the evidence insufficient to recommend vitamin D specifically for falls prevention, and advises following NHS advice on vitamin D for bone and muscle health. In elderly patients at high falls risk, follow DHSC advice on vitamin D for bone and muscle health (and correct deficiency if found), but do not prescribe it specifically as a falls intervention (NICE NG249).

The proximal myopathy-vitamin D connection is frequently missed in clinical practice because vitamin D deficiency-related myopathy mimics many common conditions (functional weakness, deconditioning, polymyalgia rheumatica, fibromyalgia). The characteristic features that point to vitamin D deficiency: difficulty rising from a chair without using arms, difficulty climbing stairs, waddling gait, and symmetrical proximal limb weakness with normal or only mildly elevated CK. Unlike inflammatory myopathy, there is no significant tenderness, fever, or systemic features. The diagnosis is confirmed by: 25-OH-D below 25 nmol/L + elevated ALP (high bone turnover) + low-normal phosphate + secondary hyperparathyroidism. Treatment response is dramatic — strength and pain typically improve within 4-6 weeks of high-dose supplementation, long before biochemical normalisation is complete. This rapid clinical improvement is a useful diagnostic confirmation.